<SEC-DOCUMENT>0001193125-22-151011.txt : 20220516
<SEC-HEADER>0001193125-22-151011.hdr.sgml : 20220516
<ACCEPTANCE-DATETIME>20220516090434
ACCESSION NUMBER:		0001193125-22-151011
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220516
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220516
DATE AS OF CHANGE:		20220516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Magenta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001690585
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38541
		FILM NUMBER:		22925874

	BUSINESS ADDRESS:	
		STREET 1:		100 TECHNOLOGY SQUARE
		STREET 2:		5TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-201-2700

	MAIL ADDRESS:	
		STREET 1:		100 TECHNOLOGY SQUARE
		STREET 2:		5TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d264834d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgta="http://www.magentatx.com/20220516" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-05-16_to_2022-05-16">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-05-16_to_2022-05-16">0001690585</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="mgta-20220516.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-05-16_to_2022-05-16"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690585</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-16</xbrli:startDate> <xbrli:endDate>2022-05-16</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-05-16_to_2022-05-16">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-05-16_to_2022-05-16" format="ixt:datemonthdayyearen">May 16, 2022</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-05-16_to_2022-05-16">MAGENTA THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-05-16_to_2022-05-16" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-05-16_to_2022-05-16">001-38541</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-05-16_to_2022-05-16">81-0724163</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-05-16_to_2022-05-16">100 Technology Square</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-05-16_to_2022-05-16">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-05-16_to_2022-05-16" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-05-16_to_2022-05-16">02139</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-05-16_to_2022-05-16">(857)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-05-16_to_2022-05-16">242-0170</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-05-16_to_2022-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-05-16_to_2022-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-05-16_to_2022-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-05-16_to_2022-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-05-16_to_2022-05-16">Common Stock, $0.001 Par Value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-05-16_to_2022-05-16">MGTA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-05-16_to_2022-05-16" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-05-16_to_2022-05-16" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2022-05-16_to_2022-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;16, 2022, Magenta Therapeutics, Inc. announced its financial results for the quarter ended March&#160;31, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in Item 2.02 of this Current Report on Form <span style="white-space:nowrap">8-K</span> (including Exhibit&#160;99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:94%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d264834dex991.htm">Press Release dated May&#160;16, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:10%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:89%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">MAGENTA THERAPEUTICS,&#160;INC.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&#160;16, 2022</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen Mahoney</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Mahoney</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial and Operating Officer</p></td></tr>
</table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d264834dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g264834g69v50.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from <FONT
STYLE="white-space:nowrap">MGTA-117</FONT> Clinical Trial and Other Program Highlights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; Clinical observations from
preliminary data at the lowest dose of <FONT STYLE="white-space:nowrap">MGTA-117</FONT> in a Phase 1/2 clinical trial indicate target binding, reduction of target cells in bone marrow, rapid drug clearance and a favorable tolerability profile &#150;
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies ongoing for CD45 antibody-drug conjugate; key
dose-ranging toxicology results expected in 2H 2022 &#150; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; Startup activities progressing for
<FONT STYLE="white-space:nowrap">MGTA-145</FONT> stem cell mobilization in sickle cell disease clinical trial; initial data anticipated in 2H 2022 &#150; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; Ended Q1 2022 with approximately $156.6&nbsp;million in cash, cash equivalents and marketable securities; maintains guidance that
cash reserves are expected to fund operating plan into Q2 2024 &#150; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA &#150; May&nbsp;16, 2022 &#150; Magenta Therapeutics (Nasdaq:
MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today reported financial results for the first quarter ending March&nbsp;31, 2022, early clinical
observations from its <FONT STYLE="white-space:nowrap">MGTA-117</FONT> clinical trial and other recent program highlights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased with the
progress of our <FONT STYLE="white-space:nowrap">MGTA-117</FONT> Phase 1/2 clinical trial. Our clinical observations from preliminary data indicate that <FONT STYLE="white-space:nowrap">MGTA-117</FONT> is functioning as designed by binding to the
intended cells with a post-dose reduction of target cells in the bone marrow, clearing the body rapidly and doing so with a favorable tolerability profile. With this level of measurable activity at our lowest dose, we believe we will collect enough
information in 2022 from the next <FONT STYLE="white-space:nowrap">1-2</FONT> cohorts to build a data set for communications with regulators for our planned transition to the transplant-eligible AML patient population. In light of the turbulence in
the capital markets, we are also pleased to have a strong cash position and a projected lower quarterly spending rate which we believe will allow us to reach our critical value inflection points, including possible <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> of <FONT STYLE="white-space:nowrap">MGTA-117</FONT> in transplant-eligible AML patients and genetic diseases with gene therapy,&#148; said Jason Gardner, President and Chief Executive Officer
of Magenta Therapeutics. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Program Highlights: </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">MGTA-117</FONT> Phase 1/2 Clinical Trial Ongoing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Clinical Trial Design and Objectives.</U> Magenta is conducting a Phase 1/2 dose-escalation clinical trial of
<FONT STYLE="white-space:nowrap">MGTA-117</FONT> in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts <FONT STYLE="white-space:nowrap">(MDS-EB).</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Clinical Trial Status and Scope of Early Clinical Observations.</U> The clinical trial has progressed from
Cohort 1 to Cohort 2 after meeting all protocol requirements for dose escalation. Patients in Cohort 1, as expected, had varying degrees of disease burden as measured in part by the percentage of leukemic cells in the bone marrow and the
bloodstream. Clinical observations were made from a preliminary data set from Cohort 1 which utilizes the trial&#146;s lowest dose of <FONT STYLE="white-space:nowrap">MGTA-117</FONT> (0.02 mg/kg). Three patients with relapsed/refractory AML
completed the safety evaluation period. A fourth patient with high disease burden did not complete the evaluation period due to disease progression with no drug-related adverse events. Cohort 2 is now open and enrolling and <FONT
STYLE="white-space:nowrap">MGTA-117</FONT> will be evaluated as a single dose of 0.04 mg/kg. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Early Clinical Observations from Cohort 1.</U><I> </I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Target Engagement/Binding:</I> Preliminary data from four patients were available for measuring target
engagement. In all patients, <FONT STYLE="white-space:nowrap">MGTA-117</FONT> was shown to bind CD117<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> cells in the blood as measured by a receptor occupancy assay. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Cell Depletion:</I> Bone marrow aspirates were obtained for three patients at baseline and post-dosing and
provided evidence supportive of biologic activity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Reductions of Erythroid Progenitor Cells in the Bone Marrow:</I> One patient had measurable reductions of
CD117+ erythroid progenitor cells in the bone marrow following <FONT STYLE="white-space:nowrap">MGTA-117</FONT> administration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Reductions of Blasts in the Bone Marrow: </I>An additional patient had an approximate 83% reduction of blasts
in the bone marrow at day 14 post-dosing (from 6% to 1%). The patient proceeded to a conditioning regimen followed by stem cell transplant. The patient&#146;s baseline profile closely resembled that of transplant-eligible AML patients due to
relatively low percentages of blasts in the bone marrow and bloodstream. Magenta believes that this outcome provides an encouraging early signal in support of <FONT STYLE="white-space:nowrap">MGTA-117&#146;s</FONT> planned transition to the
transplant-eligible AML patient population. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Rapid Drug Clearance:</I> Preliminary data from four patients were available for measuring drug clearance. In
all patients, <FONT STYLE="white-space:nowrap">MGTA-117</FONT> was deemed to be cleared 48 hours after dosing. Rapid and sufficient clearance of conditioning agents from circulation is a necessary step before stem cell infusion.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Favorable Tolerability Profile:</I> For all four patients, no unexpected or serious drug-related adverse
events were reported, no dose-limiting toxicities were observed and no drug-related adverse events higher than Grade 1 were reported. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;We are encouraged by these preliminary data. Post-dose reduction of progenitor and tumor blast cell populations in bone marrow suggests
biologic activity. We anticipate that dose escalation will lead to further drug activity and enable identification of an appropriate dose for development in patients eligible for transplant,&#148; said Dr.&nbsp;Jeff Humphrey, Chief Medical Officer
of Magenta Therapeutics. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U><FONT STYLE="white-space:nowrap">MGTA-117</FONT> Clinical Data Disclosure Expectations in 2022.</U> Magenta
expects to report additional progress updates and clinical observations from multiple dose-escalation cohorts in 2022, including providing patient-level data from this clinical trial at a scientific congress later this year. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Plans to Transition to Transplant-Eligible Patients.</U> The company anticipates that further data from the
current clinical trial showing <FONT STYLE="white-space:nowrap">MGTA-117</FONT> at high receptor occupancy levels with well-tolerated cell depletion in the blood and/or bone marrow will be supportive of the planned transition to transplant-eligible
patients. Magenta is planning to engage with regulatory authorities prior to amending the clinical trial protocol to evaluate <FONT STYLE="white-space:nowrap">MGTA-117</FONT> as a targeted conditioning agent in combination with reduced intensity
chemotherapy prior to a stem cell transplant. Simultaneously with the planned clinical trial transition, Magenta expects to initiate clinical collaboration planning with existing and potential gene therapy partners to explore <FONT
STYLE="white-space:nowrap">MGTA-117</FONT> as a single agent conditioning regimen prior to autologous stem cell gene therapy. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CD45-Antibody Drug Conjugate (ADC): Second Targeted Conditioning Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CD45 is broadly expressed on hematopoietic cells and Magenta&#146;s <FONT STYLE="white-space:nowrap">CD45-ADC</FONT> is designed to selectively target and
deplete both stem cells and lymphocytes, which would enable patients with blood cancers and autoimmune diseases to avoid the use of chemotherapy prior to stem cell transplant. </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Magenta has initiated <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies with data from a key
dose-ranging toxicology study expected in the second half of 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">MGTA-145</FONT> Stem Cell
Mobilization and Collection</B> <I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Magenta is developing <FONT STYLE="white-space:nowrap">MGTA-145,</FONT> in combination with plerixafor, to
improve stem cell mobilization from bone marrow into the bloodstream. Collection of peripheral blood stem cells, known as stem cell mobilization, is a common source of stem cells for hematopoietic stem cell transplants and gene therapy
applications.</I><I>&nbsp;</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Magenta is preparing for the initiation of a Phase 2 clinical trial in sickle cell disease (SCD) in collaboration
with bluebird bio to evaluate <FONT STYLE="white-space:nowrap">MGTA-145,</FONT> in combination with plerixafor, for mobilization and collection of stem cells in patients with sickle cell disease. Mobilization and collection are difficult in sickle
cell disease, and there is a clear unmet medical need. Initial data from this trial are expected in the second half of 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Financial Results: </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Position: </B>Cash,
cash equivalents and marketable securities as of March&nbsp;31, 2022, were $156.6&nbsp;million, compared to $176.9&nbsp;million as of December&nbsp;31, 2021. Magenta anticipates that its cash, cash equivalents and marketable securities will be
sufficient to fund its current operational plan into the second quarter of 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expenses: </B>Research and development
expenses were $16.5&nbsp;million in the first quarter of 2022, compared to $11.7&nbsp;million in the first quarter of 2021. The increase was driven primarily by the achievement of a development milestone under Magenta&#146;s license agreement
related to <FONT STYLE="white-space:nowrap">MGTA-117,</FONT> an increase in preclinical and manufacturing costs to support our <FONT STYLE="white-space:nowrap">CD45-ADC</FONT> IND enabling studies, offset by a decrease in costs related to <FONT
STYLE="white-space:nowrap">MGTA-456</FONT> which was discontinued. The increase was also due to an increase in research and development headcount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and Administrative Expenses:</B> General and administrative expenses were $7.3&nbsp;million for the first quarter of 2022, compared to
$7.0&nbsp;million for the first quarter of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Loss: </B>Net loss was $23.0&nbsp;million for the first quarter of 2022, compared to net loss of
$17.5&nbsp;million for the first quarter of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Magenta Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Magenta Therapeutics&nbsp;is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplant to more
patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise to revolutionize immune and blood reset to allow more
patients to take advantage of the curative potential of stem cell transplant as well as potentially improve eligibility for future gene therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Follow Magenta on Twitter: @magentatx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. These statements include, without limitation, implied and express statements relating to: Magenta&#146;s future business expectations,
plans and prospects; the potential of, and expectations for, Magenta&#146;s product candidate pipeline; the potential benefits and expected performance of Magenta&#146;s product candidates and programs; the development of product candidates and
advancement of preclinical and clinical programs; expectations, plans and timing for preclinical activities, clinical trials and related results involving Magenta&#146;s product candidates; timing for the receipt and disclosure of preclinical and
clinical data, clinical toxicology results, and other results involving Magenta&#146;s product candidates; timelines and expectations for patient dosing, dosing regimens and administration; the collection of enough information in 2022 from the next <FONT
STYLE="white-space:nowrap">1-2</FONT> cohorts of the <FONT STYLE="white-space:nowrap">MGTA-117</FONT> Phase 1/2 clinical trial to build a data set for communications with regulators for the planned transition to the transplant-eligible AML patient
population; the anticipated benefits of Magenta&#146;s revised operating plan; the belief that Magenta&#146;s cash position will allow it to reach critical value inflection points, including possible <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> of <FONT STYLE="white-space:nowrap">MGTA-117</FONT> in transplant-eligible AML patients and genetic diseases with gene therapy; the belief that preliminary data from Cohort 1 of the <FONT
STYLE="white-space:nowrap">MGTA-117</FONT> Phase 1/2 clinical trial provide an encouraging early signal in support of <FONT STYLE="white-space:nowrap">MGTA-117&#146;s</FONT> planned transition to the transplant-eligible AML patient population; the
anticipation that dose escalation will lead to further drug activity and enable identification of an appropriate dose for development in patients eligible for transplant; the anticipation that further data from the current clinical trial showing <FONT
STYLE="white-space:nowrap">MGTA-117</FONT> at high receptor occupancy levels with well-tolerated cell depletion in the blood and/or bone marrow will be supportive of the planned transition to transplant-eligible patients; plans to engage with
regulatory authorities prior to amending the clinical trial protocol to evaluate <FONT STYLE="white-space:nowrap">MGTA-117</FONT> as a targeted conditioning agent in combination with reduced intensity chemotherapy prior to a stem cell transplant;
the expectation that Magenta will initiate clinical collaboration planning with existing and potential gene therapy partners to explore <FONT STYLE="white-space:nowrap">MGTA-117</FONT> as a single agent conditioning regimen prior to autologous stem
cell gene therapy; preparations for the initiation of a Phase 2 clinical trial in sickle cell disease (SCD) in collaboration with bluebird bio to evaluate <FONT STYLE="white-space:nowrap">MGTA-145,</FONT> in combination with plerixafor, for
mobilization and collection of stem cells in patients with sickle cell disease; and Magenta&#146;s current anticipation regarding the ability of its cash, cash equivalents and marketable securities to fund its current operating plan into Q2 2024.
Words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;designed,&#148; &#147;endeavor,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148;
&#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;preliminary,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions are intended to
identify forward-looking statements. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The express or implied forward-looking statements included in this press release are only predictions and
are subject to a number of risks, uncertainties and assumptions, including, without limitation: volatility and uncertainty in the capital markets for biotechnology companies; uncertainties inherent in preclinical and clinical trials, and in the
availability and timing of data from ongoing and planned clinical and preclinical trials; the ability to initiate, enroll, conduct or complete ongoing and planned preclinical and clinical trials; vulnerability and/or fragility of, and the presence
of underlying disorders in, the patient population for the clinical trials of Magenta&#146;s product candidates, including the <FONT STYLE="white-space:nowrap">MGTA-117</FONT> Phase 1/2 clinical trial in patients with relapsed/refractory acute
myeloid leukemia and myelodysplasia-excess blasts; the delay of any current or planned preclinical or clinical trials or the development of Magenta&#146;s product candidates; whether results from preclinical or earlier clinical trials will be
predictive of the results of future trials; interactions with regulatory agencies such as the U.S. Food and Drug Administration; the expected timing of submissions for regulatory approval to conduct or continue trials or to market products;
Magenta&#146;s ability to successfully demonstrate the safety and efficacy of its product candidates; whether Magenta&#146;s cash resources will be sufficient to fund Magenta&#146;s foreseeable and unforeseeable operating expenses and capital
expenditure requirements; and risks, uncertainties and assumptions regarding the impact of the continuing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Magenta&#146;s business, operations, preclinical activities, clinical trials,
strategy, goals and anticipated timelines. These and other risks are described in additional detail in Magenta&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2022, expected to be
filed on or about May&nbsp;16, 2022, and its other filings made with the Securities and Exchange Commission from time to time. Any forward-looking statements contained in this press release represent Magenta&#146;s views only as of today and should
not be relied upon as representing its views as of any subsequent date. Magenta explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jill Bertotti, Real Chemistry (advisor to
Magenta) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">714-225-6726</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jbertotti@realchemistry.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Magenta Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In
thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 16,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 11,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (22,950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (17,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,799,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,567,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEET DATA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In
thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mgta-20220516.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 5/16/2022 4:33:44 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:mgta="http://www.magentatx.com/20220516"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.magentatx.com/20220516"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgta-20220516_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgta-20220516_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mgta-20220516_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 5/16/2022 4:33:44 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mgta-20220516_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 5/16/2022 4:33:44 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mgta-20220516.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g264834g69v50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g264834g69v50.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M;^&[?4397%K82K!<WFTV]U/?123%XQ<UKWMV0]%IV.B_9/\ VN_'V@_L6?M
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MW[,7PI\3?&#_ ()Q?M0>!O"\,FL>+F^+-YKFC6MM\S:]K'A+3_A_XAFL;($
M3W&H+IES#;I\H::ZA' /!%7@_)_D&S7D>8_#[4_^"9<7P7TW6/BOIOQ3L/C%
MHFDQ:1XN^&MAXE^)(U;6O%FGQ+9WK:'$+RWT>SLK^[C,RVUW=67V(SM;2QJT
M&'2Y$M=XAJO(^G/VU?#'@7P1X$_X)U^'/AS8:QHO@6U^+.AWGA?2_$G]I1Z]
M8Z7J]]X7UJ.VU:+6S]N@U!'U%Q+#<_O(FS&<;!526D;=/^ "TOY'J7_!6)T2
MR_91W,J_\7\TX_,P7I#99ZD=,BB:V\A+3R.:_;I\:Z'\(OV[OV/_ (L>.FO=
M+\!:!X=UV/4]<AL;F]CA>*]UNUNTB@M8WENY;5=>TRXFA@62803%TC?;@DO=
MDGLD"V[&7_P40^)7A/XI^$/V._'-SJ/B6\_9-\;_ !!EU3XB7VF6FJZ<=1TE
M+O1HM-;4;)XH[B"9M$C\6RV<,T:S%TE:%!<I$%)=.BZ_+_(:T^1\[?%BZ_8W
M/[2/['T7[).A:+:V<'QC\(P^-_%/ABT\06WAC4KEO%/A!] \.QW>N.(M1\06
M<+WMY<BVC,D46I6PN)&:94B);QM?3U_4%HGT/T7_ &S?V?-4U;5%^+OA/3I]
M3@%K:6GQ T?3X7FU%;*PQ&GB6QMH@7O!'IP,%W%$ID5+:"=595F*?095C8TX
MO"U)<N[IM[7?V7VN]4WINM-#\[XMX?J5:O\ :N$INHGRK%4XJ\K1LO:Q2U=H
MKEJ):V2DKVD?%OQ[-P?C-\05N.+>+6+>#0U7 MT\)PZ78+X16P"_*-._X1T:
M>T.SY-K$CDFN[!6^KT[;Z\W^*[YOG>Y_J?X-0RVGX:\)+*U35!X*+ER6_CN<
M_K'-;[?M+J5]4DELD>N?L0OJZ?'FT33//&GR>$O$0\1+%N\DZ;&+1K%KH#CY
M=9-@(RW(+N%ZM7/FBBL/YJ2Y?7K^%SY7Z0\<O? M.6)4/KD<PPWU-NW/SN-1
M5E#K;V"ESVTTA?5(_7KQ%<WL>GR6.D,%UK4TDL],D(W)9RRKLDU2=<'_ $:R
M1C<,#C>T:0@[YD!^>5DUV1_#-1R47&&DY:1\O/TCO^'4M:'H]EX>T;2M"TY#
M'8:/I]IIMHK$%_(LH$MXVD8 ;Y66,,[8RS,S'DT-MMOJ]0IPC2A"G#2,$HKT
M2L5KWPOX9U'5]-\0:CX=T*_U[1E9=(UN]TC3[K5]*5BY9=-U*>W:XL58NY(A
MD3.]L]32LETV+V\K!>>%_#.H:QI_B*_\.Z%?>(-(1HM)UR\TC3[G6-,C;S=T
M>GZG-;M<V2'SILK#(@/FO_>.2WX!MY"W7A?PU?:U8>([[P]H=YXATJ)H-+UZ
M[TFPN-:TV%O.#0V&J36[7-G$WVBXRD,J ^?)D?.V3] V\C)UGX<_#WQ'K=AX
MF\0^!/!NN^(])\K^R]?UGPQHFJ:WIOV>0RP?8-5O;&6ZL_+E)=/*E3:QW+@\
MT67;8-AUSX-TRSTWQ='X/M-&\%^(?%=IJ)N?$VD:!IR7AUVZM[Q+/Q!J<5NM
MLVN7EK>7DET!<S[I&,@,B^:S4K6VT#;Y'YDZC^S9_P %+;GPY>?#;_AKOX?Z
MIX*OK2;2+CQ3J/AN[MOB!-H\ZF"9)=0@\-37@O);9F5I5UHS_,<7BD[ZGEGM
M>R'HNFQ]R?LQ?L]>&_V8?A%HGPL\.7]QK)M+J]UG7_$%W EI/KWB/56C;4-2
M^Q122)8VPC@M;6WMEDE\FVLK=&DE=6DDJ*Y5;L+]#T2X^%/POO/$B^,KOX;^
M KKQ>DZ7*^*;CPAX?G\1K<QD&.Y&MRZ>UX+A2!MD\[<,<&BR[;!M\CH=9\+^
M&?$;Z?)XA\.Z%KTFD70O=*?6=)L-4?3+Q2C+=Z>U];RFRN@T49\V'8^8UY^4
M8=OP#;R#6_"_AGQ,+$>)/#NA>(!IER+W31K>D:?JHT^\7 6[L1?V\OV2Y 48
MEBVN,#GBBWX!MY$'B;P;X0\:V46F>,O"OAOQ;IL$ZW4.G^)M#TS7K*&Y12BW
M$5IJMK/%'.JLP$BH& 8C/-%EVV#;R'WGA'PGJ'A[_A$;_P ,>'K[PI]FBLO^
M$8O-%TVY\/?8[<J8+3^Q9K9K/[-&40I%Y.Q=BX P*++:VBZ!MY&39?#+X;Z9
M::-I^G?#[P186'AN]DU+P]96?A30;6TT'497@DEO]&MX+!8],O7DMK=VGMEC
MD9K>,EB44A62Z6L'Z';_ -/TI_H&WD>#?%?]G#X7_&"YL]1\3:=?6&MV-NEE
M#KOAV\72]2>QB+-#8W>Z":WO;:)G8QB>WD:+<PC9 Q!Z:&+K89-4Y>Z_LO57
M[^7R/O.#_$CBO@>G5P^28R#P5:7/+"XFG[;#JI9)U(1O&5.;22DZ<XJ5ESJ5
ME;H/A3\%/A_\&M/O+'P5I<T-QJ31-JNLZE<MJ&M:GY&_[/'=7KJH2WB\Q]EO
M!'#"I=F$>]V8S6Q%6NTZDK\NR6B7HOUW//XLXWXBXUQ=+%9]C?;K#IJA0IP5
M+#T%*W-[.E'12E9<TY.4Y62<FDDO55AC21I0@$K!59SRQ1?NH">B Y.T8&23
MU-8;'R>WR)* /-/%EO</XV^'7E:SKEC!=7^KQ7FG6&J36FG:A'INCWFJVZ7U
MFGRW ^TP1AN5W1@QME"16]-I4JWNQ;BHV;2NKNSL^FA]!EDZ<<GS]2PF'K3I
MTZ#IU:E&,ZM%U*].C)TIO6'N2=M':7O*TE<\8D\;^-)/#^NO--J5@+3P!\5[
M_3=675=.>35;S2?&>GZ=IU_!%$IDTRXL;25K>)[@ *+C)!,;&NGV5)3C9)_O
M*2:L]$X-M>:;UT['U\,DR:&.P<81IUN?,\DI5:+HUK4:=? 5:U:G)MVK1JU(
MJ4HP=WR:-*21H^.-5U_0-,\*16MWXTTVY;1_&5ZS)XIT[5O[-U6'6?"=AHNK
M>+M6N9WBOO"UC+JSM<HJ70BM[MMT+"(M'-*,)2J74'9P5N5QNK2;4%I:3MIM
M=G-DF%P.-Q&:RJT\!7IQQ& II2PE6A[:@\/C:F(H8&A"*E2QE:-!*BVZ?/5@
MK5%S6EUJ>,]2'QA_L62]OCH9TS_A$C:II]VNA'Q;'I*^+WU!-6:U-M]O.G-)
M9?8OM1E BW&+C-1[**PW-9<R?/NN;DOR)<N]KZWM8\QY/A_]4GBXT:2QBJ_7
MO:.M#ZS]1==X!4704^?V:JI5O;>RY?>MSVT/.K#5?'#>!-&U!KSQLUGXAU+X
M:16IU37]+TW7=4U#45NY/%;:/JZ2,VF>';Q3I+6RW,D;YCNA$D4<T8.KC2]K
M)6@G"-1OEBW%)6Y+KK):WMY;V/>KX7)HYUB\.J6 57 4LWE-4<-6JX:C2I*"
MP*K4&DJV*I/VRJN$91UI.I*<H2/0]2U_5=-O=1TQ-6O+9X$^!\5A9W5_#>WF
M-:\7W&FZVHN3N.I2W=K \%Q.A<2"%V4CDUC&$6HOE3_C7=K+2"<=.EF]$?/X
M7 87$4*&(>&A-3?$#J3A"5.%\/@8UL/[BLJ2I3DITX.W+S*+OHA7;4-(?QU<
MV_B+Q#,UO\2O >BVJ:AJ\M];V&FZK>^ [N_L[*&9=MO',VOZE$>K>3,D0(6)
M,-*+5)<D5^[FW96U2G:[\N5/U'RX?$QR.G/ X:"EE.8UYNE15.=6K1AF4*52
MI*+O*4%AZ,ELN>+DTW*5RW;6-8T+QQJUCXUGLO%5QJ7BK0K73;_6+>ST7P^F
MC>)9=)TVU@M!;R?V5?2Z=!9K_:313RF36UN"DJFWC5/EA.E%T[TTHR;2U=XW
M>O5)WTTVMH.I'!X/'9+A:^4QJ993HX+$SJTJ,IXC%.OA(UJLY3<H^VIPJRG;
M#J4(*-!TKP?M)OT'X?ZA!J/A:QEA?62]O<:IIUW%X@OX=4U6TU'2]4O-/U&P
MN=4MWDBU);6]MYX([J.64310QOYCEB3C5CRU&M%LURJRLTFFETNNG0\+.Z$L
M-F5>$O86E&E5A+#4Y4:,Z56C"K2J0HR494?:4Y1G*E*,7"<I1Y5:QVE9GDA0
M 4 % !0 4 % !0 4 <?KO_(S>!_^O_7/_3!?5I'X*GHOS/2PG^X9M_U[P_\
MZD4SQ+6?^1*UC_LFOQ>_]2>UKIC_ !8_]?:7_I)]=@O^1QA/^QMDO_J-,Y'X
M=_\ )*+/_L1OC7_Z5Z/5U_\ >)?XZ7Y2/2S[_DI\1_V,<B_]-U3U^W_Y<_\
MLKW_ +A9:P?_ +B_4^6>U;_L3_\ N>)P?Q<_Y-WT/_KW\#_^C;&M<-_O<O\
MM_\ 4]WA3_DNL5_BS'_TBH<ZG_(]?LQ?]B:__IH2J_Y=8W_%^IUK_D3>(/\
MV'_^[#/<M3_U/C'_ +*-X)_]"\ US1_Y=_\ 7N?Y3/D*.^5?]BW'?GF)\]^-
M?^1[_:,_[)SI?_HG1JZZ?\/"?X__ )(^XRG_ )$_ 7_8TK_^E53Z+^"O_)*O
J O\ V +;_P!#EKDQ/\:IZ_HCX?BS_DI,X_[")?DCU&L#YT* "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140041395165784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 16, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 16,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MAGENTA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-0724163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Technology Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">242-0170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGTA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d264834d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgta-20220516.xsd" xlink:type="simple"/>
    <context id="duration_2022-05-16_to_2022-05-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690585</identifier>
        </entity>
        <period>
            <startDate>2022-05-16</startDate>
            <endDate>2022-05-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-05-16_to_2022-05-16">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-05-16_to_2022-05-16"
      id="Hidden_dei_EntityCentralIndexKey">0001690585</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-05-16_to_2022-05-16">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-05-16_to_2022-05-16">2022-05-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-05-16_to_2022-05-16">MAGENTA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-05-16_to_2022-05-16">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-05-16_to_2022-05-16">001-38541</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-05-16_to_2022-05-16">81-0724163</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-05-16_to_2022-05-16">100 Technology Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-05-16_to_2022-05-16">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-05-16_to_2022-05-16">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-05-16_to_2022-05-16">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-05-16_to_2022-05-16">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-05-16_to_2022-05-16">242-0170</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-05-16_to_2022-05-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-05-16_to_2022-05-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-05-16_to_2022-05-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-05-16_to_2022-05-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-05-16_to_2022-05-16">Common Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-05-16_to_2022-05-16">MGTA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-05-16_to_2022-05-16">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-05-16_to_2022-05-16">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2022-05-16_to_2022-05-16">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "02+!47/1\W54$  #7$   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)6877/:.!2&K[N_0L/T8G<FB2WQF0YAQB$D95HH&V@[LSM[(6P!FM@6E>4
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M4$L! A0#%     @ D$BP5+S:#PSO    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ D$BP5)E<G",0!@  G"<
M !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " "02+!47/1\W54$  #7$   &               @($."   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ D$BP5)^@&_"Q @  X@P
M  T              ( !F0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "0
M2+!4EXJ[',     3 @  "P              @ %U#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " "02+!4'#AEZC\!   \ @  #P              @ %>$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ D$BP5"0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ D$BP5&60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d264834d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d264834d8k.htm">d264834d8k.htm</File>
    <File>d264834dex991.htm</File>
    <File>mgta-20220516.xsd</File>
    <File>mgta-20220516_lab.xml</File>
    <File>mgta-20220516_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d264834d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d264834d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgta-20220516_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgta-20220516_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mgta-20220516.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mgta",
   "nsuri": "http://www.magentatx.com/20220516",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d264834d8k.htm",
      "contextRef": "duration_2022-05-16_to_2022-05-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d264834d8k.htm",
      "contextRef": "duration_2022-05-16_to_2022-05-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.magentatx.com//20220516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-22-151011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-151011-xbrl.zip
M4$L#!!0    ( )!(L%2U^!' &@\  *)C   .    9#(V-#@S-&0X:RYH=&WM
M7>F3VK@2_[Y5^S^HR,L64S6 #<P,,,>K688DU&:. O)VZWU)"5N -L9V)'F
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M%LMGE%*9H/&#*Y8Q?@QV"]T#6>$Q_'@+\ @"ZS@ 7B /7CP<X<Q!7L:)\B"
MH 7!L;OB;@'2URKUA.6]$1FU*.JQ[:!%0XL9 KU0+@$NQC&R@%QYHD @AK'#
M(R^0HHN30-DGQ$ @L&EL<J4RT%"!B0UM)$'K_$SC RR9CXW!$U5VZC(2*UHS
M?#8.^C'H 4!VVRV7"(5@72+@1ZD30J(82@9W8'VT>$#7(PXDA&E$ =@L4JT
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M(,H4KF"+Z@KM=83G'!YH=Y7$DU/,1YW*3&4L4L=2S&J.![X)_*P8[Q!)I !
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M.1#PFEU\8A>7W:M6[_3BZ_5#XWDD KV-70[F.FB==P^ R&,-X)1>!.3%(2B
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MX[A[S.DAJ!T=(G"3W_-&F893^CZW'H"JV:P;B.;)Q.AZCJ+A3</=O(Z +#6
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M;UJI(01FMATTS(HR,RO4^4# ME5O5B8Y@%7'1K89X-_W.."*0-B%Z;:*YV(
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M_ U02P$"% ,4    " "02+!4M?@1P!H/  "B8P  #@              @ $
M    9#(V-#@S-&0X:RYH=&U02P$"% ,4    " "02+!4*UL60I8<   ML@
M$0              @ %&#P  9#(V-#@S-&1E>#DY,2YH=&U02P$"% ,4
M" "02+!4A^F4GT4#  !6"P  $0              @ $++   ;6=T82TR,#(R
M,#4Q-BYX<V102P$"% ,4    " "02+!4%XJ'X(L&  "J1@  %0
M    @ %_+P  ;6=T82TR,#(R,#4Q-E]L86(N>&UL4$L! A0#%     @ D$BP
M5+$[)://!   /RP  !4              ( !/38  &UG=&$M,C R,C U,39?
=<')E+GAM;%!+!08     !0 % $ !   _.P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
